Bordet Scientific Publications

Bordet Scientific Publications

  • Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

  • Auteurs Blanc J, Carnot A, Barthélémy P, Casert V, Sautois B, Van den Brande J, Vanhaudenarde V, Staudacher L, Seront E, Debien V, Ameye L, Kotecki N, Rothé F, Rorive S, Fantoni JC, Tricard T, Roumeguère T, Awada A, Martinez Chanza N
  • Auteurs (entité) AWADA AHMAD HUSSEIN
  • Revue J Immunother Cancer
  • Date de publication 2025-05
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.
  • Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

  • Auteurs Blanc J, Carnot A, Barthélémy P, Casert V, Sautois B, Van den Brande J, Vanhaudenarde V, Staudacher L, Seront E, Debien V, Ameye L, Kotecki N, Rothé F, Rorive S, Fantoni JC, Tricard T, Roumeguère T, Awada A, Martinez Chanza N
  • Auteurs (entité) DEBIEN VERONIQUE
  • Revue J Immunother Cancer
  • Date de publication 2025-05
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.
  • Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

  • Auteurs Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E
  • Auteurs (entité) DEBIEN VERONIQUE
  • Revue Clin Breast Cancer
  • Date de publication 2025-05
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.
  • Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

  • Auteurs Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E
  • Auteurs (entité) DE AZAMBUJA EVANDRO
  • Revue Clin Breast Cancer
  • Date de publication 2025-05
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.
  • Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

  • Auteurs Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E
  • Auteurs (entité) AGOSTINETTO ELISA
  • Revue Clin Breast Cancer
  • Date de publication 2025-05
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.
  • Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

  • Auteurs Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E
  • Auteurs (entité) MOREAU MICHEL
  • Revue Clin Breast Cancer
  • Date de publication 2025-05
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.
  • Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

  • Auteurs Lobo-Martins S, Debien V, Agostinetto E, Sirico M, Carvalho GS, Jacobs F, Molinelli C, Bonadio RC, Bergmann P, Souza CP, Testa L, Nishimuni M, João Rossi A, Guimarães GK, Moreau M, De Giorgi U, Bines J, Santoro A, Taylor D, Duhoux FP, Barchiesi G, Lambertini M, Piccart M, de Azambuja E
  • Auteurs (entité) PICCART MARTINE
  • Revue Clin Breast Cancer
  • Date de publication 2025-05
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.
Erasme hospital

Erasmus Hospital

View all of Erasmus's scientific publications

Huderf hospital

Queen Fabiola Children's Hospital

View all scientific publications from the Queen Fabiola Children's Hospital

Bordet hospital

Jules Bordet Institute

View all of Jules Bordet's scientific publications